Agile Therapeutics (AGRX) Given a $4.00 Price Target by HC Wainwright Analysts

Agile Therapeutics (NASDAQ:AGRX) has been given a $4.00 price target by investment analysts at HC Wainwright in a report released on Monday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 479.71% from the company’s current price.

A number of other brokerages also recently weighed in on AGRX. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, March 14th. ValuEngine upgraded Agile Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Agile Therapeutics currently has a consensus rating of “Hold” and an average price target of $8.00.

Shares of AGRX stock opened at $0.69 on Monday. The company has a market capitalization of $23.63 million, a price-to-earnings ratio of -0.76 and a beta of 2.12. Agile Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $5.60.



Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.05. equities analysts anticipate that Agile Therapeutics will post -0.73 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its stake in Agile Therapeutics by 113.1% in the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 20,654 shares during the period. A.R.T. Advisors LLC grew its stake in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after acquiring an additional 29,995 shares during the period. Dimensional Fund Advisors LP grew its stake in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after acquiring an additional 55,937 shares during the period. Broadfin Capital LLC acquired a new stake in Agile Therapeutics in the fourth quarter valued at approximately $964,000. Finally, Renaissance Technologies LLC grew its stake in Agile Therapeutics by 313.7% in the fourth quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after acquiring an additional 277,600 shares during the period. 72.15% of the stock is owned by hedge funds and other institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply